Oxamate, an LDHA Inhibitor, Inhibits Stemness, Including EMT and High DNA Repair Ability, Induces Senescence, and Exhibits Radiosensitizing Effects in Glioblastoma Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125710 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Takuma Hashimoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Radiation Biology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Cellular Senescence, DNA Repair, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Education, Culture, Sports, Science and Technology of Japan, Grand-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and Technology of Japan.
Abstract (Originalsprache)
Enhancement of glycolysis has been reported in tumor cells, and it is believed that this enhancement is important for maintaining the stemness of tumor cells and contributes to malignant phenotypes. Here, we investigated the effects of Oxamate, which inhibits glycolysis by blocking the conversion of pyruvate to lactate, on radiosensitivity and its molecular mechanisms in T98G glioblastoma cells. Oxamate significantly enhanced radiosensitivity by delaying DNA repair, as indicated by the persistence of γ-H2AX foci up to four days post-irradiation. Mechanistically, Oxamate suppressed the expression and phosphorylation of key DNA repair factors. Furthermore, Oxamate induced apoptosis and promoted cellular senescence, as evidenced by the accumulation of SA-β-gal and the upregulation of pS15-p53 and p21. In addition, Oxamate downregulated EGFR expression, reduced the levels of stem cell markers, and modulated epithelial–mesenchymal transition (EMT) markers, suggesting a potential suppression of EMT-related pathways. Together, these results demonstrate that Oxamate enhances radiosensitivity in glioblastoma cells through multiple mechanisms, including the inhibition of DNA repair, induction of apoptosis and senescence, and suppression of cancer stem cell properties and EMT. Our findings provide new insights into the potential use of Oxamate as a radiosensitizer and warrant further investigation of its clinical application in glioblastoma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Radiation Biology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
ORCID-Profile: Takuma Hashimoto, Khaled Hatabi, Yoshio Hosoi
Förderung
- the Ministry of Education, Culture, Sports, Science and Technology of Japan
- Grand-in-Aid for Scientific Research
- Ministry of Education, Culture, Sports, Science and Technology of Japan
Zitieren
APA
Hashimoto, T., Ushikubo, G., Arao, N., Hatabi, K., Tsubota, K., & Hosoi, Y. (2025). Oxamate, an LDHA Inhibitor, Inhibits Stemness, Including EMT and High DNA Repair Ability, Induces Senescence, and Exhibits Radiosensitizing Effects in Glioblastoma Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125710
Vancouver
Hashimoto T, Ushikubo G, Arao N, Hatabi K, Tsubota K, Hosoi Y. Oxamate, an LDHA Inhibitor, Inhibits Stemness, Including EMT and High DNA Repair Ability, Induces Senescence, and Exhibits Radiosensitizing Effects in Glioblastoma Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125710
BibTeX
@article{Hashimoto2025,
author = {Hashimoto, Takuma and Ushikubo, Go and Arao, Naoya and Hatabi, Khaled and Tsubota, Kazuki and Hosoi, Yoshio},
title = {Oxamate, an LDHA Inhibitor, Inhibits Stemness, Including EMT and High DNA Repair Ability, Induces Senescence, and Exhibits Radiosensitizing Effects in Glioblastoma Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125710}
}
EUVIMED